Next-Gen Obesity Drugs Compared: The 2026 Pipeline

The Obesity Drug Pipeline in April 2026

The landscape of obesity pharmacotherapy is evolving at unprecedented speed. Two years ago, semaglutide (Wegovy) and tirzepatide (Zepbound) represented the state of the art. Today, a new generation of agents is advancing through clinical development — each with a distinct mechanism, route of administration, or dosing frequency designed to address different patient needs.

This article compares the most clinically advanced next-generation obesity drugs as of April 2026, evaluating their mechanisms, available efficacy data, development stage, and potential position in the treatment landscape. All cross-trial comparisons are observational and subject to the limitations inherent in comparing data across different study designs, patient populations, and durations.

The Comparison Table

TRE = treatment-regimen estimand. SC = subcutaneous.

Retatrutide: The Efficacy Leader

Retatrutide (Eli Lilly) is the only triple hormone receptor agonist in the obesity pipeline, simultaneously targeting GIP, GLP-1, and glucagon receptors. This triple mechanism produces the highest weight loss of any agent in the current landscape.

Key data. In the Phase 3 TRIUMPH-4 trial, retatrutide 12 mg produced -28.7% mean weight loss at 68 weeks in adults with obesity and knee osteoarthritis (on-treatment estimand). At 9 mg, weight loss was -26.4%. Nearly 40% of participants at 12 mg lost 30% or more of their body weight. The Phase 2 NEJM publication had previously reported up to -24.2% at 48 weeks, and the Phase 3 data confirmed and extended this efficacy.

Differentiating features. Beyond raw weight loss, retatrutide’s glucagon receptor component provides distinct advantages in liver fat reduction (82.4% relative reduction in Phase 2) and energy expenditure enhancement. These effects are not replicated by any other agent in the pipeline except survodutide, which also includes glucagon receptor agonism but lacks the GIP component.

Safety considerations. Retatrutide’s adverse event profile includes standard GLP-1 class gastrointestinal effects (nausea 43.2%, diarrhea 33.1% at 12 mg) plus a novel dysesthesia signal (20.9% at 12 mg) not seen with other agents. Discontinuation due to adverse events was 18.2% at 12 mg, though substantially lower (12.1%) in the BMI 35 and above subgroup.

Timeline. Eli Lilly plans to submit the TRIUMPH program data to the FDA in late 2026, with a possible approval decision in mid-2027 and commercial launch in early 2028.

Orforglipron (Foundayo): The First Oral GLP-1

Orforglipron, now marketed as Foundayo, became the first oral non-peptide GLP-1 receptor agonist to receive FDA approval on April 1, 2026. Developed by Eli Lilly, it represents a fundamentally different approach to obesity pharmacotherapy: delivering GLP-1 receptor agonism through a daily pill rather than an injection.

Key data. The Phase 3 ATTAIN-1 trial reported -12.4% weight loss at the 17.2 mg dose using the treatment-regimen estimand (which accounts for all participants regardless of adherence). The on-treatment estimand was approximately -11.1%. While these numbers are more modest than injectable agents, they are clinically meaningful and comparable to or exceeding older injectable GLP-1 agonists.

Differentiating features. Orforglipron’s primary advantage is convenience: a daily oral pill with no injection requirement, no cold chain storage, and minimal food timing restrictions. It is a small-molecule non-peptide, meaning it does not require the SNAC absorption enhancer used in oral semaglutide (Rybelsus). The pricing is also notable: $25 per month for insured patients and $149 per month for self-pay through LillyDirect, substantially below the current market pricing for injectable GLP-1 agonists.

Clinical position. Foundayo is positioned for the broadest possible patient population — patients who prefer oral medications, those with needle aversion, and those seeking an accessible first-line pharmacological option for weight management. It is available immediately via LillyDirect.

Amycretin: Novo Nordisk’s Oral Challenger

Amycretin is Novo Nordisk’s oral dual agonist targeting both GLP-1 and amylin receptors. It represents the company’s response to the oral GLP-1 category that Eli Lilly opened with orforglipron.

Key data. Phase 2 results reported approximately 22% weight loss at 36 weeks, which is a striking result for an oral agent and substantially exceeds orforglipron’s Phase 3 efficacy. If this magnitude of weight loss holds in Phase 3 trials with larger populations and longer durations, amycretin would be the most effective oral obesity drug in development.

Differentiating features. The amylin receptor component adds a mechanism not present in pure GLP-1 agonists. Amylin is a pancreatic peptide co-secreted with insulin that suppresses glucagon, slows gastric emptying, and promotes satiety through central nervous system effects. The combination of GLP-1 and amylin agonism in an oral formulation could offer a compelling efficacy-convenience combination.

Caveats. Phase 2 data are preliminary. Weight loss magnitudes frequently decrease between Phase 2 and Phase 3 due to larger and more heterogeneous patient populations, intent-to-treat analyses, and longer trial durations. The 36-week duration is also shorter than typical Phase 3 efficacy endpoints (usually 52-72 weeks). Phase 3 results will be needed to confirm whether amycretin’s early promise translates to sustained, real-world-relevant efficacy.

Timeline. Phase 3 trials have been initiated. Assuming standard development timelines, FDA submission would not be expected before 2028, with potential approval in 2029.

MariTide: Amgen’s Monthly Injection

MariTide (maridebart cafraglutide, formerly AMG 133) is Amgen’s antibody-based approach to obesity pharmacotherapy. It combines an anti-GIP antibody with a GLP-1 receptor agonist peptide, creating a single molecule that simultaneously blocks GIP signaling and activates GLP-1 receptors.

Key data. Phase 2 results showed approximately 15-20% weight loss, with the notable feature that the drug’s long half-life allows monthly (or potentially even less frequent) dosing. The weight loss appeared to continue without plateauing during the Phase 2 observation period, suggesting that longer treatment could yield greater effects.

Differentiating features. MariTide’s primary clinical differentiator is dosing frequency. A monthly subcutaneous injection, if clinically validated, would offer the least treatment burden of any injectable obesity medication. The anti-GIP mechanism is also pharmacologically distinct — while retatrutide and tirzepatide activate the GIP receptor, MariTide inhibits it. This opposing approach to GIP signaling, producing weight loss through both pathways, remains a subject of pharmacological debate.

Caveats. Phase 2 data are promising but preliminary. The anti-GIP mechanism is novel and raises questions about long-term metabolic effects that only extended Phase 3 data can address. Manufacturing antibody-peptide conjugates at scale presents greater complexity and cost than peptide or small-molecule production.

Timeline. Phase 3 trials are ongoing. Amgen has not disclosed a specific regulatory submission timeline, but market entry before 2028-2029 is unlikely.

Survodutide: The Other Dual Agonist

Survodutide (Boehringer Ingelheim/Zealand Pharma) is a dual GLP-1/glucagon receptor agonist — sharing two of retatrutide’s three receptor targets but lacking GIP receptor activity.

Key data. Phase 2 results in obesity showed approximately 18-19% weight loss at 46 weeks. Survodutide has also shown significant efficacy in MASH (metabolic dysfunction-associated steatohepatitis), with its glucagon component driving substantial liver fat reduction — mechanistically similar to retatrutide.

Differentiating features. Survodutide’s glucagon receptor agonism provides metabolic benefits beyond pure appetite suppression, including increased energy expenditure and direct hepatic fat mobilization. Its MASH efficacy data are among the strongest in the field and may define its primary clinical niche if it cannot match the weight loss of triple agonists in the obesity indication.

Caveats. The absence of GIP receptor agonism means survodutide has a mechanistically narrower profile than retatrutide. Phase 3 results will determine whether the dual mechanism is sufficient to compete with triple agonism on weight loss or whether survodutide will be primarily positioned for liver disease.

Timeline. Phase 3 trials are ongoing for both obesity and MASH indications. Regulatory submissions could begin in 2027, with potential approval in 2027-2028.

VK2735: Viking’s Early-Stage Contender

VK2735 (Viking Therapeutics) is a subcutaneous GLP-1/GIP dual agonist that attracted significant attention based on early Phase 2 data.

Key data. Phase 2 results showed approximately 14.7% weight loss at 13 weeks — a notable result given the short treatment duration. If the weight loss trajectory continued at a similar rate over a standard 52-68 week period, the total efficacy could be competitive with established agents.

Differentiating features. Viking is a smaller biotech company compared to Lilly, Novo, and Amgen, which may affect development speed, manufacturing scale, and commercial reach. The 13-week Phase 2 data, while promising, represent the earliest-stage evidence in this comparison. Viking is also developing an oral formulation of VK2735, which could provide optionality similar to Eli Lilly’s injectable/oral portfolio approach.

Caveats. The 13-week duration is substantially shorter than any other data in this comparison. Weight loss curves for GLP-1 agonists typically do not plateau until 40-68 weeks, making extrapolation from 13-week data unreliable. Phase 3 data are needed to evaluate VK2735’s position in the landscape.

Timeline. Phase 3 trials have been initiated. Given Viking’s smaller organizational scale, the development timeline may extend beyond 2028 for potential regulatory submission.

What Differentiates Retatrutide

Among the next-generation agents, retatrutide occupies a distinct position for several reasons:

Highest demonstrated efficacy. At -28.7% in Phase 3, retatrutide has the strongest weight loss data supported by Phase 3-level evidence. Only amycretin’s Phase 2 data approaches this range for an oral agent, and that remains unconfirmed at Phase 3.

Triple receptor mechanism. Retatrutide is the only agent targeting three metabolic hormone receptors simultaneously. The glucagon component provides energy expenditure enhancement and liver fat reduction that single- and most dual-agonists do not replicate.

Liver fat reduction. The 82.4% relative liver fat reduction observed in Phase 2 is among the most substantial reported for any agent in the MASLD/MASH space, positioning retatrutide for a potential role in liver disease beyond its obesity indication.

Broadest indication potential. Lilly is pursuing retatrutide across obesity, type 2 diabetes, OSA, knee OA, cardiovascular outcomes, kidney disease, and liver disease — a broader indication footprint than any competing pipeline agent.

Tolerability trade-offs. The dysesthesia signal (20.9% at 12 mg) and higher GI adverse event rates distinguish retatrutide from competitors in safety profile. These trade-offs will need to be weighed against the efficacy advantage in clinical decision-making.

The Emerging Treatment Paradigm

The diversity of the 2026 obesity drug pipeline points toward a future treatment paradigm that matches drug characteristics to patient profiles:

For patients who prefer oral treatment or have mild-to-moderate obesity: Orforglipron (Foundayo) is already available and provides a convenient, affordable entry point. If amycretin’s Phase 3 data confirm its Phase 2 promise, it could offer greater oral efficacy in the future.

For patients needing significant weight loss with weekly injection convenience: Retatrutide, tirzepatide (Zepbound), and survodutide offer strong efficacy profiles with once-weekly dosing. Retatrutide leads on raw efficacy.

For patients who prefer the least frequent dosing: MariTide’s monthly injection could define a new standard for dosing convenience if Phase 3 confirms its efficacy and safety.

For patients with liver disease comorbidity: Retatrutide and survodutide, both with glucagon receptor agonism, have the strongest mechanistic basis and clinical data for liver fat reduction.

This is not a winner-take-all market. The obesity population exceeds 100 million adults in the United States alone, with diverse clinical needs, preferences, and comorbidity profiles. Multiple effective agents with distinct characteristics will find their clinical roles.

Frequently Asked Questions

Which next-gen obesity drug produces the most weight loss?

Based on Phase 3 data, retatrutide (Eli Lilly) produces the highest reported weight loss at -28.7% at 68 weeks. However, this comparison is limited because most competing agents have only Phase 2 data from shorter durations. Amycretin (Novo Nordisk) showed approximately 22% at 36 weeks in Phase 2, which is notable for an oral agent. Phase 3 data from multiple agents are expected throughout 2026-2027 and will provide clearer comparative evidence.

Is orforglipron (Foundayo) better than retatrutide?

These drugs serve different clinical needs and are not directly comparable as “better” or “worse.” Orforglipron (Foundayo) is an FDA-approved oral daily pill producing approximately 12.4% weight loss, priced at $25-149 per month, and available immediately. Retatrutide is an investigational weekly injection producing 28.7% weight loss, not yet approved. Orforglipron offers convenience and accessibility; retatrutide offers maximal efficacy. Both are Eli Lilly products designed for complementary patient populations.

When will retatrutide be available?

Eli Lilly plans to submit the TRIUMPH program data to the FDA in late 2026. Assuming standard or priority review timelines, an approval decision could come in mid-2027, with commercial launch potentially in early 2028. This timeline depends on the remaining Phase 3 readouts and the FDA review process.

What about CagriSema from Novo Nordisk?

CagriSema (cagrilintide plus semaglutide) is another important pipeline agent, combining a long-acting amylin analog with semaglutide. Phase 3 results showed clinically meaningful weight loss, though the primary endpoint comparison versus semaglutide alone did not meet statistical superiority in the initial readout. CagriSema remains in regulatory development and could provide another treatment option in the incretin therapy space.

Will these new drugs be affordable?

Pricing varies significantly. Orforglipron (Foundayo) launched at $25 per month for insured patients and $149 per month for self-pay — substantially below the approximately $1,000 per month list price of current injectable GLP-1 agonists. Retatrutide pricing has not been announced. The competitive dynamics of the expanding obesity drug market, combined with political and regulatory pressure on drug pricing, suggest that pricing may trend downward as more options become available, though this is not guaranteed.